Amendment to the Claims:

1 – 9 (Cancelled)

10. (Currently Amended) A combined preparation comprising a naked binding member, which binds to both SCR1 and SCR2 of CD55, and an active agent, said combined preparation being for simultaneous, separate or sequential use in the treatment of cancer, wherein said active agent is a chemotherapeutic agent, a pain relief agent, an antibody, or an anti-emetic.

11. (Previously Presented) The combined preparation according to claim 10, wherein said active agent is doxorubicin, paclitaxel, 5-fluorouracil, irinotecan or cisplatin.

12. (Original) The combined preparation according to claim 10 wherein said active agent is an antibody.

13. (Previously Presented) The combined preparation according to claim 13 wherein said active agent is an anti-CD20 antibody; an anti-VEGF antibody; an anti-CD171A antibody; an anti-CEA; anti-idiotypic mAb; an anti-HMFG anti-idiotypic mAb; an anti-EGFR antibody; or an anti-HER2 antibody.

14. (Cancelled)

15. (Original) A pharmaceutical composition for the treatment of cancer, wherein the composition comprises a naked binding member that binds to both SCR1 and SCR2 of CD55 and a pharmaceutically acceptable excipient, diluent or carrier.

16. (Cancelled)

17. (Original) A method of neutralizing the complement activation inhibition activity of CD55, comprising administration of a naked binding member which specifically binds to SCR1 and SCR2 of CD55.

18. (Original) A method of enhancing complement deposition comprising administration of a naked binding member which specifically binds to SCR1 and SCR2 of CD55.

19. (Original) A method of treating cancer comprising administration of a therapeutically effective amount of a naked binding member which specifically binds to SCR1 and SCR2 of CD55 to a mammal in need thereof.

20. (Cancelled)

21. (Previously Presented) The method according to claim 19 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid cancer.

22. (Previously Presented) The method according to claim 19 wherein the binding member is an antibody or a fragment thereof.

23. (Previously Presented) The method according to claim 19 wherein the binding member binds to SCR1 amino acids 83-93, and SCR2 amino acids 101-112 and 145-157, of the amino acid sequences shown in Figure 1b.

24. (Previously Presented) The method according to claim 19 wherein the binding member comprises one or more of the CDRs of the antibody, or a fragment thereof, produced by the cell line deposited at ATCC under accession number HB9173.

25. (Previously Presented) The method according to claim 19 wherein the binding member is the antibody 791T/36 produced by the hybridoma cell deposited at ATCC under accession number HB9173.